Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
Epithalon Variants
Modified epithalon-like peptides marketed for anti-aging despite essentially no variant-specific human evidence.
Tier Dmedium risk
02· Subject
Hexarelin
GHRP-class secretagogue with stronger GH stimulation and studied sleep-endocrine effects.
Tier B-Chigh risk
01 · At a glance
| Decision factor | Epithalon Variants | Hexarelin | Selank |
|---|---|---|---|
| Primary fit | longevity & anti-aging and sleep & relaxation comparisons | muscle growth & strength and sleep & relaxation comparisons | cognitive & neuroprotection and sleep & relaxation comparisons |
| Evidence | Tier D | Tier B-C | Tier B-C |
| Risk | medium | high | med-high |
| Experience level | intermediate | advanced | intermediate |
| Budget tier | mid | mid | mid |
| Administration route | subcutaneous, intramuscular | subcutaneous, intravenous | intranasal |
02 · Use case & timing
| Decision factor | Epithalon Variants | Hexarelin | Selank |
|---|---|---|---|
| Goal fit | Longevity & Anti-Aging, Sleep & Relaxation | Muscle Growth & Strength, Sleep & Relaxation, GH Axis Optimization | Cognitive & Neuroprotection, Sleep & Relaxation, Anxiety & Mood |
| What users compare it for | Claims center on telomere support, sleep quality, and anti-aging signals, but evidence is largely anecdotal. | GH-axis modulation; sleep architecture research interest. | Anxiolytic/calm focus effects reported in limited clinical settings. |
| Onset timeline | Any claimed anti-aging effect would require long follow-up and remains unproven. | Acute endocrine effects; sleep effects studied overnight. | Some rapid responders described in clinical abstracts, but not broad RCT-grade evidence. |
| Main tradeoff | Evidence and product availability can still be uneven, so documentation matters more than hype. | Potential upside comes with much more safety and screening caution than lower-risk alternatives. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | Epithalon Variants | Hexarelin | Selank |
|---|---|---|---|
| Adverse effects | Unknown human safety; peptide modification may increase immune-reactivity or formulation risk. | Endocrine spillover (ACTH, cortisol, prolactin). | Limited Western regulatory data; higher scrutiny warranted. |
| Contraindications | No formal human contraindications established; avoid treating variant products as equivalent to better-studied approved therapies. | No formal label. | No established label. |
| Interaction notes | No clear interaction map; avoid assuming safety when combined with other experimental longevity agents. | Unknown; caution with other GH-axis compounds. | Animal diazepam interaction explored; do not translate to human guidance. |
| Regulatory status | Not approved | Not approved | Not approved |
| FDA flag | FDA compounding caution | FDA status unclear | FDA compounding caution |
| WADA status | Not listed | WADA S2 | Status unclear |
04 · Age & monitoring
| Decision factor | Epithalon Variants | Hexarelin | Selank |
|---|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet | No age guidance yet |
| Life-stage note | Not yet documented | Not yet documented | Not yet documented |
| Monitoring burden | Not specified | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | Epithalon Variants | Hexarelin | Selank |
|---|---|---|---|
| Typical cycle cost | No reliable estimate yet | No reliable estimate yet | €20.64 |
| Estimated monthly cost | No reliable estimate yet | No reliable estimate yet | €27.52 |
| Cost confidence | No estimate | No estimate | High confidence |
06 · Before you buy
| Decision factor | Epithalon Variants | Hexarelin | Selank |
|---|---|---|---|
| Tracked vendor listings | 0 listings | 0 listings | 3 listings |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | No tracked product page yet, so sourcing takes more manual review. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly | Usually stack-friendly |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.